The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries-Reference-Cited by-同舟云学术

The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries

Published:2012-08-30 Issue:12 Volume:14 Page:1129-1136
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Khunti K.¹,Caputo S.²,Damci T.³,Dzida G. J.⁴,Ji Q.⁵,Kaiser M.⁶,Karnieli E.⁷,Liebl A.⁸,Ligthelm R. J.⁹,Nazeri A.¹⁰,Orozco-Beltran D.¹¹,Pan C.¹²,Ross S. A.¹³,Svendsen A. L.¹⁴,Vora J.¹⁵,Yale J.-F.¹⁶,Meneghini L. F.¹⁷,

Affiliation:

1. Department of Health Sciences; University of Leicester; Leicester UK

2. Servizio di Diabetologia; Policlinico Gemelli, Universita'Cattolica; Rome Italy

3. Department of Endocrinology, Diabetes and Metabolism; Istanbul University, Cerrahpasa Medical School; Istanbul Turkey

4. Department of Internal Diseases; Medical University of Lublin; Lublin Poland

5. Department of Endocrinology and Metabolism; Xijing Hospital, Fourth Military Medical University; Xian China

6. Practice for Internal Medicine and Diabetology; Frankfurt Germany

7. Endocrinology, Diabetes & Metabolism; Rambam Medical Center and Rappaport Faculty of Medicine, Technion; Haifa Israel

8. Center for Diabetes and Metabolism, m&i-Fachklinik Bad Heilbrunn; Bad Heilbrunn Germany

9. EHM Clinic; Hoofddorp The Netherlands

10. Global Medical Affairs; Novo Nordisk A/S; Søborg Denmark

11. Catedra of Family Medicine, Department of Medicine; University Miguel Hernandez; Alicante Spain

12. Department of Endocrinology; Chinese PLA General Hospital; Beijing China

13. Department of Medicine; University of Calgary; Calgary Alberta Canada

14. Department of Biostatistics & Epidemiology; Novo Nordisk A/S; Søborg Denmark

15. Department of Diabetes and Endocrinology; Royal Liverpool University Hospital; Liverpool UK

16. McGill Nutrition and Food Science Centre; Royal Victoria Hospital; Montreal Quebec Canada

17. University of Miami Miller School of Medicine; Miami FL USA

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2012.01665.x/fullpdf

Reference35 articles.

1. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the real-life effectiveness and care patterns of diabetes management (RECAP-DM) study;Alvarez;Diabetes Obes Metab,2008

2. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study;Calvert;Br J Gen Pract,2007

3. Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain;Costi;Acta Diabetol,2010

4. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial;Hollander;Diabetes Obes Metab,2011

5. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes;Philis-Tsimikas;Clin Ther,2006

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on Aleppo et al. The Effect of Discontinuing Continuous Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care 2021;44:2729–2737;Diabetes Care;2022-03-29

2. Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial;Diabetes & Metabolism Journal;2022-01-31

3. Incidence and Risk Factors Associated with Outpatient Hypoglycemia in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Study;Endocrine Research;2020-07-14

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study

;ClinicoEconomics and Outcomes Research;2020-04

5. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus;Current Medical Research and Opinion;2020-01-19